HLA‐associated adverse drug reactions ‐ scoping review
| Autor: | Henriette E. Meyer zu Schwabedissen, Chiara Jeiziner, Kurt E. Hersberger, Ursina Wernli, Katja Suter |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Heterozygote
030213 general clinical medicine medicine.medical_specialty Drug-Related Side Effects and Adverse Reactions MEDLINE Reviews RM1-950 Review Human leukocyte antigen 030226 pharmacology & pharmacy General Biochemistry Genetics and Molecular Biology law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial HLA Antigens law Internal medicine medicine Humans Genetic Predisposition to Disease Drug reaction General Pharmacology Toxicology and Pharmaceutics Alleles Genetic association business.industry Histocompatibility Testing General Neuroscience General Medicine Carbamazepine Systematic review Therapeutics. Pharmacology Public aspects of medicine RA1-1270 business |
| Zdroj: | Clinical and Translational Science Clinical and Translational Science, Vol 14, Iss 5, Pp 1648-1658 (2021) |
| ISSN: | 1752-8062 1752-8054 |
| DOI: | 10.1111/cts.13062 |
| Popis: | Alleles of the human leukocyte antigen (HLA) system have been associated with the occurrence of idiosyncratic adverse drug reactions (ADRs). Accordingly, it is assumed that pre‐emptive testing for the presence of certain HLA alleles (HLA‐typing) could prevent these ADRs in carriers. In order to perceive the current evidence for HLA‐associated ADRs, we conducted a scoping review according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA). The literature search on PubMed and on Embase was carried out on the July 8 and 9, 2020, respectively. To be included in the scoping review, the studies had to investigate an association of any HLA‐associated ADR with any small molecule approved and available on the Swiss market. We considered English and German primary literature published since 2002. A total of 149 studies were included, whereof most were retrospective, whereas one was a prospective randomized controlled trial. The majority of the studies (n = 33) described the association of HLA‐B*15:02 with carbamazepine. It was not possible to directly compare the studies, as they were too heterogeneous in terms of the ADR definition, the HLA alleles, the number of participants, and the study types. Therefore, we summarized the results in a descriptive manner. Even if an interpretation of the outcomes remains open, the descriptive overview revealed the prevailing complexity and uncertainty in the field. For the future, consistent definitions on the different phenotypes need to be established and applied and the reporting of association studies should follow a harmonized structure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |